ATE446972T1 - Il-1 bindende antikörper und fragmente davon - Google Patents

Il-1 bindende antikörper und fragmente davon

Info

Publication number
ATE446972T1
ATE446972T1 AT06773749T AT06773749T ATE446972T1 AT E446972 T1 ATE446972 T1 AT E446972T1 AT 06773749 T AT06773749 T AT 06773749T AT 06773749 T AT06773749 T AT 06773749T AT E446972 T1 ATE446972 T1 AT E446972T1
Authority
AT
Austria
Prior art keywords
fragments
binding antibodies
seq
amino acid
acid sequence
Prior art date
Application number
AT06773749T
Other languages
English (en)
Inventor
Linda Masat
Mary Haak-Frendscho
Gang Cheng
Arnold Horwitz
Marina Roell
Original Assignee
Xoma Technology Ltd
Linda Masat
Mary Haak-Frendscho
Chen Gang
Arnold Horwitz
Marina Roell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd, Linda Masat, Mary Haak-Frendscho, Chen Gang, Arnold Horwitz, Marina Roell filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE446972T1 publication Critical patent/ATE446972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
AT06773749T 2005-06-21 2006-06-21 Il-1 bindende antikörper und fragmente davon ATE446972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69283005P 2005-06-21 2005-06-21
PCT/US2006/024261 WO2007002261A2 (en) 2005-06-21 2006-06-21 IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
ATE446972T1 true ATE446972T1 (de) 2009-11-15

Family

ID=37595818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06773749T ATE446972T1 (de) 2005-06-21 2006-06-21 Il-1 bindende antikörper und fragmente davon

Country Status (23)

Country Link
US (11) US7531166B2 (de)
EP (5) EP3056511B1 (de)
JP (2) JP4931919B2 (de)
KR (3) KR20140139618A (de)
CN (2) CN101228188A (de)
AT (1) ATE446972T1 (de)
AU (1) AU2006262179B2 (de)
BR (1) BRPI0612273C1 (de)
CA (2) CA2873914A1 (de)
CY (3) CY1109715T1 (de)
DE (1) DE602006010072D1 (de)
DK (4) DK2314623T3 (de)
ES (5) ES2827247T3 (de)
HU (1) HUE029021T2 (de)
IL (2) IL188094A (de)
MX (2) MX2007016032A (de)
NZ (1) NZ565138A (de)
PL (4) PL2163562T3 (de)
PT (3) PT1899378E (de)
RU (1) RU2518295C2 (de)
SI (4) SI1899378T1 (de)
WO (1) WO2007002261A2 (de)
ZA (1) ZA200800555B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1899378T1 (sl) 2005-06-21 2010-02-26 Xoma Technology Ltd IL-1Beta vezavna protitelesa in njihovi fragmenti
CA2963828A1 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
LT2068889T (lt) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
CN101616690B (zh) * 2006-12-20 2015-11-25 爱克索马美国有限责任公司 用于治疗IL-1β相关疾病的方法
CA2687499C (en) * 2007-05-29 2017-11-28 Novartis Ag New indications for anti-il-1-beta therapy
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
US8637029B2 (en) * 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
PL2293816T3 (pl) * 2008-06-06 2013-04-30 Xoma Us Llc Sposoby leczenia reumatoidalnego zapalenia stawów
AU2009289545A1 (en) * 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for improvement of beta cell function
BRPI0919979A2 (pt) * 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
EP2391652A4 (de) * 2009-01-29 2013-01-02 Abbott Lab Il-1-bindende proteine
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2010128092A1 (en) * 2009-05-06 2010-11-11 Novartis Ag ANTI-IL1-β ANTIBODY COMBINATION THERAPY
SG176265A1 (en) * 2009-05-29 2012-01-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
LT2805731T (lt) * 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
BR112012007365A2 (pt) * 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
EA201201526A1 (ru) * 2010-05-07 2013-06-28 Ксома Текнолоджи Лтд. Способы лечения состояний, связанных с il-1b
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
CA2826564C (en) 2011-02-08 2018-05-15 Abbvie Inc. Treatment of osteoarthritis and pain
CN103492416A (zh) 2011-04-15 2014-01-01 默克专利股份公司 用于癌症中使用的抗il-1r1抑制剂
JP6184942B2 (ja) * 2011-06-03 2017-08-23 メゾブラスト，インコーポレーテッド 神経疾患を治療するまたは予防する方法
WO2013007763A1 (en) 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
TWI461192B (zh) 2011-07-20 2014-11-21 Twi Biotechnology Inc 降低血脂異常病患之糖化血色素的醫藥組成物
DE102011083595A1 (de) * 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
EP2794657B1 (de) * 2011-12-19 2017-10-11 Xoma (Us) Llc Verfahren zur behandlung von akne
ES2534782T3 (es) * 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
EP2977386A1 (de) * 2012-08-31 2016-01-27 Argen-X Nv Verfahren zur herstellung von antikörpermolekülen mit inter-spezies- und intra-target-kreuzreaktivität
WO2014068132A1 (en) * 2012-11-05 2014-05-08 Delenex Therapeutics Ag Binding members to il-1 beta
WO2014095808A1 (en) * 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
KR101989551B1 (ko) * 2013-02-15 2019-09-30 알-팜 인터내셔널, 엘엘씨. IL-1β 억제제 조성물 및 이의 용도
WO2014194166A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
BR112016013347B1 (pt) * 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
CA2986064A1 (en) 2015-05-18 2016-11-24 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) regimen
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
EP4252629A3 (de) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
CN108218978B (zh) * 2016-12-13 2020-05-12 沈阳何氏眼产业集团有限公司 一种重组白细胞介素18及其制备方法与应用
CA3046093A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TW201904993A (zh) 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
EP3655961A4 (de) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology Zellatlas von gesundem und erkranktem barrieregewebe
TWI850773B (zh) 2017-08-31 2024-08-01 日商田邊三菱製藥股份有限公司 可溶性il-33受體的用途
RU2020113234A (ru) 2017-09-13 2021-10-13 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
EP3836954B1 (de) 2018-08-13 2025-05-07 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
US20220356240A1 (en) * 2019-09-26 2022-11-10 Beth Israel Deaconess Medical Center, Inc. Anti-inflammatory therapy in arrhythmogenic cardiomyopathy (acm)
WO2021116789A1 (en) 2019-12-09 2021-06-17 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
US12486321B2 (en) * 2020-01-21 2025-12-02 Tavotek Biotechnology (Jiangsu) Co., Ltd Agents that interfere with IL-1BETA receptor signalling
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用
AU2024304141A1 (en) * 2023-06-13 2026-01-08 Merck Sharp & Dohme Llc Methods of using cyclic peptides for trapping interleukin-1 beta
CN116832720B (zh) * 2023-06-19 2025-11-21 广州聚焦生物科技有限公司 一种发光免疫检测的冻干微球及其制备方法
WO2025147631A1 (en) * 2024-01-04 2025-07-10 William Marsh Rice University Encapsulated cells for the treatment of respiratory diseases and disorders

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493543A (en) * 1893-03-14 Lap-ring
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
EP0569687B1 (de) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
DE3588241T2 (de) 1984-05-18 2002-12-05 Massachusetts Institute Of Technology, Cambridge Menschliche IL-1 cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5474899A (en) 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5077218A (en) * 1988-05-05 1991-12-31 Oregon Lions Sight And Hearing Foundation Inc. Eye transport apparatus
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0364778B1 (de) 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antikörper gegen Interleukin-1-beta
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69032251T2 (de) * 1989-02-27 1998-08-13 Massachusetts Institute Of Technology, Cambridge, Mass. Il-1, dessen biologische aktivität inhibiert ist
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0617706B1 (de) 1991-11-25 2001-10-17 Enzon, Inc. Multivalente antigen-bindende proteine
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
ATE408012T1 (de) * 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
AU695323B2 (en) 1994-09-09 1998-08-13 Takeda Chemical Industries Ltd. Sustained release preparation containing metal salt of a peptide
EP0787179A4 (de) * 1994-10-20 1999-05-19 Merck & Co Inc INTERLEUKIN-1-g(b) DEFIZIERTE TRANSGENE TIERE
CN100350973C (zh) * 1994-10-21 2007-11-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
EP0817620B1 (de) 1995-03-28 2002-01-30 Fidia Advanced Biopolymers, S.R.L. Nanosphären mit einem biokompatiblen polysaccharid
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6455254B1 (en) 1995-07-18 2002-09-24 Diversa Corporation Sequence based screening
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US6004788A (en) 1995-07-18 1999-12-21 Diversa Corporation Enzyme kits and libraries
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6489145B1 (en) 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
US6368798B1 (en) 1995-12-07 2002-04-09 Diversa Corporation Screening for novel bioactivities
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6344328B1 (en) 1995-12-07 2002-02-05 Diversa Corporation Method for screening for enzyme activity
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
JP4018154B2 (ja) * 1996-10-31 2007-12-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Ｉｃｅ阻害ペプチド
EP0977779A1 (de) * 1997-04-21 2000-02-09 Schering Corporation Tierisch cytokine, verwandte reagentien und verfahren
IL140125A0 (en) 1998-06-17 2002-02-10 Maxygen Inc Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP1165757A1 (de) 1999-03-05 2002-01-02 Maxygen, Inc. Erzeugung eines merkmals durch rekombination von split-gen sequenzen
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1282435A2 (de) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitoren zur behandlung von erkrankungen
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6864047B2 (en) * 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
CA2461665A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US6673552B2 (en) 2002-01-14 2004-01-06 Diversa Corporation Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps
EP1481010A2 (de) 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1-beta-analoga
US7572770B2 (en) 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
EP1531757B1 (de) 2002-07-19 2016-09-07 Omeros Corporation Biologisch abbaubare triblock-copolymere, syntheseverfahren daf r und hydrogele und daraus hergestellte biologische materialien
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
WO2004039834A2 (en) 2002-11-01 2004-05-13 Alk-Abelló A/S Recombinant protein variants
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US20050159590A1 (en) 2003-08-25 2005-07-21 Galit Rotman Variants of interleukin-1 receptor antagonist: compositions and uses thereof
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
WO2005084696A1 (en) 2004-03-08 2005-09-15 Universita'degli Studi Di Milano Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr
EP1576952A1 (de) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel-Mikrosphären mit verbessertem Freisetzungsprofil
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
SI1899378T1 (sl) 2005-06-21 2010-02-26 Xoma Technology Ltd IL-1Beta vezavna protitelesa in njihovi fragmenti
FR2895611B1 (fr) 2005-12-23 2008-02-22 Thales Sa Architecture et procede pour controler le transfert d'informations entre utilisateurs
US8479265B2 (en) * 2008-07-02 2013-07-02 Oracle International Corporation Usage based authorization

Also Published As

Publication number Publication date
EP2163562B1 (de) 2013-09-18
EP3056511B1 (de) 2020-08-05
KR101502920B1 (ko) 2015-03-17
DK1899378T3 (da) 2010-02-01
SI1899378T1 (sl) 2010-02-26
US20080044414A1 (en) 2008-02-21
EP2322552A3 (de) 2011-07-20
US9206252B2 (en) 2015-12-08
US20090246210A1 (en) 2009-10-01
PT1899378E (pt) 2010-01-26
US20090060923A1 (en) 2009-03-05
DK2314623T3 (da) 2012-09-17
US20090226461A1 (en) 2009-09-10
MX2007016032A (es) 2008-03-10
HK1158218A1 (en) 2012-07-13
CA2873914A1 (en) 2007-01-04
PL2163562T3 (pl) 2014-03-31
US8377442B2 (en) 2013-02-19
US20090214568A1 (en) 2009-08-27
DE602006010072D1 (de) 2009-12-10
US20120014967A1 (en) 2012-01-19
HK1157351A1 (en) 2012-06-29
SI2314623T1 (sl) 2012-11-30
WO2007002261A3 (en) 2007-07-12
US7744866B2 (en) 2010-06-29
ES2827247T3 (es) 2021-05-20
ES2569917T3 (es) 2016-05-13
IL188094A (en) 2011-01-31
CN102775493B (zh) 2015-10-28
PL2322552T3 (pl) 2016-08-31
CY1113153T1 (el) 2016-04-13
NZ565138A (en) 2012-02-24
PT2163562E (pt) 2013-12-19
EP2314623A1 (de) 2011-04-27
JP4931919B2 (ja) 2012-05-16
BRPI0612273B1 (pt) 2019-02-05
US7744865B2 (en) 2010-06-29
AU2006262179A1 (en) 2007-01-04
BRPI0612273A2 (pt) 2009-01-27
PL2314623T3 (pl) 2012-11-30
BRPI0612273C1 (pt) 2021-05-25
US7695717B2 (en) 2010-04-13
CY1114851T1 (el) 2016-12-14
US20140004125A1 (en) 2014-01-02
EP2322552B1 (de) 2016-02-10
US20100061998A1 (en) 2010-03-11
RU2518295C2 (ru) 2014-06-10
EP2163562A2 (de) 2010-03-17
SI2322552T1 (sl) 2016-07-29
JP2011254835A (ja) 2011-12-22
ES2391334T3 (es) 2012-11-23
MX348154B (es) 2017-05-30
US20090214545A1 (en) 2009-08-27
US7582742B2 (en) 2009-09-01
ZA200800555B (en) 2009-09-30
EP2322552A2 (de) 2011-05-18
KR20130076901A (ko) 2013-07-08
EP1899378B1 (de) 2009-10-28
CY1109715T1 (el) 2014-08-13
EP1899378A2 (de) 2008-03-19
IL188094A0 (en) 2008-03-20
PL1899378T3 (pl) 2011-03-31
US7988968B2 (en) 2011-08-02
JP2008543340A (ja) 2008-12-04
DK2322552T3 (en) 2016-04-25
EP3056511A3 (de) 2016-11-23
BRPI0612273B8 (pt) 2020-01-14
CN101228188A (zh) 2008-07-23
AU2006262179B2 (en) 2011-05-12
EP2314623B1 (de) 2012-07-04
US7531166B2 (en) 2009-05-12
KR20080039875A (ko) 2008-05-07
CN102775493A (zh) 2012-11-14
CA2612760A1 (en) 2007-01-04
EP3056511A2 (de) 2016-08-17
DK2163562T3 (da) 2013-12-09
US7943121B2 (en) 2011-05-17
HUE029021T2 (en) 2017-02-28
HK1140781A1 (en) 2010-10-22
CA2612760C (en) 2015-05-12
IL202630A (en) 2011-01-31
US20100055110A1 (en) 2010-03-04
US7829093B2 (en) 2010-11-09
US7829094B2 (en) 2010-11-09
KR101366450B1 (ko) 2014-03-14
EP2163562A3 (de) 2010-10-20
KR20140139618A (ko) 2014-12-05
ES2439709T3 (es) 2014-01-24
SI2163562T1 (sl) 2014-01-31
ES2335232T3 (es) 2010-03-23
RU2008102135A (ru) 2009-07-27
WO2007002261A2 (en) 2007-01-04
PT2314623E (pt) 2012-10-02
US20090060918A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ596295A (en) Anti-5T4 antibodies and uses thereof
DK1706424T3 (da) FC-region varianter
DK1392359T3 (da) Specifikke bindingsproteiner og deres anvendelser
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
RU2017124859A (ru) Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
IS2786B (is) Prótín sem bindast viðtaka Nogo
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
EP3300739A3 (de) An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
ATE449177T1 (de) Staphylococcus epidermidis antigene
EP2098594A4 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
CY1117395T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899378

Country of ref document: EP

EEIH Change in the person of patent owner